Halozyme Therapeutics has a Zacks Rank of #2 (Buy), while Amicus Therapeutics has a Zacks Rank of #3 (Hold) right now. Investors should feel comfortable knowing that HALO likely has seen a stronger ...

But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Of these, ...

HALO is a #3 (Hold) on the Zacks Rank, with a VGM Score of B. It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 13.55; value investors ...

On Friday, Halozyme Therapeutics, Inc. (HALO) stock saw a decline, ending the day at $45.65 which represents a decrease of $-8.31 or -15.40% from the prior close of $53.96. The stock opened at $48.81 ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily ...

On Friday, Halozyme Therapeutics, Inc. (HALO) stock saw a modest uptick, ending the day at $57.15 which represents a slight increase of $6.58 or 13.01% from the prior close of $50.57. The stock opened ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. Many investors also have a go-to methodology that helps guide their buy ...

HALO sits at a Zacks Rank #3 (Hold), holds a Value Style Score of B, and has a VGM Score of A. Compared to the Medical - Biomedical and Genetics industry's P/E of 23.8X, shares of Halozyme ...